Antibiotic treatment regimens for bone infection after debridement: a study of 902 cases

Abstract

Background: Our aim was to investigate the clinical efficacy and complications of antibiotic treatment regimens for patients with bone infection. Methods: We retrospectively analysed patients with bone infection admitted to our hospital between March 2013 and October 2018. After surgical debridement was performed, the patients were divided into three groups: IV group (intravenous antibiotics for 2 weeks); oral group (intravenous antibiotics for 2 weeks followed by oral antibiotics for 4 weeks); and rifampicin group (intravenous antibiotics for 2 weeks followed by oral antibiotics plus rifampicin for 4 weeks). The infection control rate and complications were compared among the three groups. Results: A total of 902 patients were enrolled. The infection sites included 509 tibias, 228 femurs, 32 humeri, 23 radii and ulnae, 40 calcanei, and 47 miscellaneous sites, as well as 23 multiple-site infections. After at least 6 months of follow-up, 148 (16.4%) patients had an infection recurrence. The recurrence rate of the IV group was 17.9%, which was not significantly higher than the recurrence rates of the oral group (10.1%) and rifampicin group (10.5%), P = 0.051. The incidence of abnormal alanine aminotransferase (ALT) levels in the IV group was 15.1%, which was lower than that in the oral group (18.0%) and rifampicin group (27.4%), P = 0.026. The rates of proteinuria in the three groups were 3.2, 4.5, and 9.3%, respectively, P = 0.020. Conclusions: After debridement of bone infection, short-term antibiotic treatment regimens might offer similar rates of infection eradication while avoiding the risk of renal and hepatic damage associated with prolonged antibiotic use. The level of clinical relevance: Stage III.

Systemic Antimicrobial Treatment of Chronic Osteomyelitis in Adults: A Narrative Review

“…Therefore, the findings from implant-associated infection studies may not be directly applicable to native bacterial osteomyelitis, and more research is needed. In our research, some RCTs showed improved treatment outcomes with the addition of rifampicin [12,38,43,44] with non-statistically significant results, while others observed no significant difference [35,40,41,45]. Common limitations of studies included: investigation of S. aureus bacteremia without separate analysis of patients with osteomyelitis [36,37], small size, exclusion of patients with comorbidities [40,41], unbalanced arms in terms of size [43,44] or different patient comorbidities in study arms [38,43,44].…”

Tailoring Biomaterials Ameliorate Inflammatory Bone Loss

“…[105] Antibiotic therapy is the most primary and traditional method for combating bacteria. [105,106] However, the presence of biofilm impedes the permeation of antibiotics, and the administration of antibiotics tends to readily elicit bacterial resistance due to their specific and limited target sites. [107,108] In contrast, biomaterials are difficult to trigger bacterial tolerance because biomaterials have many passive antibacterial mechanisms, which contain direct cell wall or membrane destruction, ROS production, and intracellular components damage.…”

Preparation and Characterization of Vancomycin Hydrochloride-Loaded Mesoporous Silica Composite Hydrogels

“…Until now, repairing infected jaw defects has remained a challenge due to its high recurrence rate for oral and maxillofacial surgeons ( Zhang et al, 2019 ). To our knowledge, infection is due to the local presence of pathogenic bacteria in the lesion, and once an infected jaw defect occurs, it may require multiple surgical debridements and long-term systemic antibiotic therapy, which may lead to the development of secondary injury, adverse antibiotic reactions, or lifelong functional impairment, and increase the financial burden on the health-care system ( Vestby et al, 2020 ; Wang et al, 2020 ). Therefore, antimicrobial drug carriers, a topical strategy, have become an adjunct to the prevention and treatment of infections in jaw defects ( Alazzawi et al, 2021 ; Han et al, 2021 ).…”